Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.15
ZTS's Cash to Debt is ranked lower than
90% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. ZTS: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
ZTS' s 10-Year Cash to Debt Range
Min: 0.1  Med: 0.18 Max: N/A
Current: 0.15
Equity to Asset 0.18
ZTS's Equity to Asset is ranked lower than
94% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ZTS: 0.18 )
Ranked among companies with meaningful Equity to Asset only.
ZTS' s 10-Year Equity to Asset Range
Min: 0.12  Med: 0.20 Max: 0.69
Current: 0.18
0.12
0.69
Interest Coverage 8.07
ZTS's Interest Coverage is ranked lower than
82% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. ZTS: 8.07 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s 10-Year Interest Coverage Range
Min: 2.3  Med: 7.55 Max: 13.28
Current: 8.07
2.3
13.28
F-Score: 6
Z-Score: 4.10
M-Score: -2.53
WACC vs ROIC
7.63%
20.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 20.35
ZTS's Operating margin (%) is ranked higher than
82% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. ZTS: 20.35 )
Ranked among companies with meaningful Operating margin (%) only.
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53  Med: 13.66 Max: 19.73
Current: 20.35
-4.53
19.73
Net-margin (%) 8.74
ZTS's Net-margin (%) is ranked higher than
60% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. ZTS: 8.74 )
Ranked among companies with meaningful Net-margin (%) only.
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62  Med: 7.93 Max: 12.18
Current: 8.74
-3.62
12.18
ROE (%) 32.87
ZTS's ROE (%) is ranked higher than
90% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. ZTS: 32.87 )
Ranked among companies with meaningful ROE (%) only.
ZTS' s 10-Year ROE (%) Range
Min: 11.26  Med: 16.74 Max: 51.8
Current: 32.87
11.26
51.8
ROA (%) 6.43
ZTS's ROA (%) is ranked higher than
63% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ZTS: 6.43 )
Ranked among companies with meaningful ROA (%) only.
ZTS' s 10-Year ROA (%) Range
Min: 7.28  Med: 8.22 Max: 8.86
Current: 6.43
7.28
8.86
ROC (Joel Greenblatt) (%) 24.23
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. ZTS: 24.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88  Med: 31.26 Max: 34.3
Current: 24.23
25.88
34.3
Revenue Growth (3Y)(%) 4.00
ZTS's Revenue Growth (3Y)(%) is ranked lower than
58% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ZTS: 4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZTS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 4.00 Max: 8.4
Current: 4
0
8.4
EBITDA Growth (3Y)(%) 21.40
ZTS's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. ZTS: 21.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZTS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 21.40 Max: 36.2
Current: 21.4
0
36.2
EPS Growth (3Y)(%) 33.30
ZTS's EPS Growth (3Y)(%) is ranked higher than
84% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ZTS: 33.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZTS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 33.30 Max: 66.2
Current: 33.3
0
66.2
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Pioneer Investments 2,203,980 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Robert Olstein 178,000 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
Q4 2014

ZTS Guru Trades in Q4 2014

Jim Simons 650,500 sh (New)
Steven Cohen 1,718,300 sh (New)
Bill Ackman 41,569,646 sh (+650.78%)
Mario Gabelli 626,893 sh (+187.59%)
George Soros 4,106,735 sh (+1.86%)
Ruane Cunniff 173,423 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Pioneer Investments 2,202,773 sh (-0.05%)
Vanguard Health Care Fund 9,178,657 sh (-15.00%)
Robert Olstein 141,000 sh (-20.79%)
John Keeley 62,164 sh (-21.81%)
First Eagle Investment 820,467 sh (-62.26%)
RS Investment Management 212,262 sh (-91.48%)
» More
Q1 2015

ZTS Guru Trades in Q1 2015

Caxton Associates 100,000 sh (New)
Paul Tudor Jones 8,800 sh (New)
Louis Moore Bacon 55,000 sh (New)
Jim Simons 1,822,794 sh (+180.21%)
Pioneer Investments 2,879,512 sh (+30.72%)
Bill Ackman 41,823,145 sh (+0.61%)
First Eagle Investment 820,467 sh (unchged)
George Soros 4,106,735 sh (unchged)
Robert Olstein 141,000 sh (unchged)
Bill Ackman 41,823,145 sh (unchged)
RS Investment Management Sold Out
John Keeley 61,856 sh (-0.50%)
Mario Gabelli 614,785 sh (-1.93%)
Ruane Cunniff 139,936 sh (-19.31%)
Vanguard Health Care Fund 6,175,407 sh (-32.72%)
Steven Cohen 142,400 sh (-91.71%)
» More
Q2 2015

ZTS Guru Trades in Q2 2015

Richard Perry 2,000,000 sh (New)
Steven Cohen 4,246,900 sh (+2882.37%)
Paul Tudor Jones 30,630 sh (+248.07%)
Louis Moore Bacon 95,000 sh (+72.73%)
Mario Gabelli 695,142 sh (+13.07%)
Ruane Cunniff 151,149 sh (+8.01%)
Pioneer Investments 2,881,279 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Bill Ackman 41,823,145 sh (unchged)
Caxton Associates Sold Out
John Keeley 60,874 sh (-1.59%)
Jim Simons 1,510,800 sh (-17.12%)
Vanguard Health Care Fund 5,115,837 sh (-17.16%)
George Soros 2,744,635 sh (-33.17%)
First Eagle Investment 508,942 sh (-37.97%)
Robert Olstein 20,000 sh (-85.82%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 52.40
ZTS's P/E(ttm) is ranked lower than
71% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. ZTS: 52.40 )
Ranked among companies with meaningful P/E(ttm) only.
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31  Med: 36.01 Max: 59.81
Current: 52.4
27.31
59.81
Forward P/E 23.20
ZTS's Forward P/E is ranked lower than
52% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. ZTS: 23.20 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 54.50
ZTS's PE(NRI) is ranked lower than
71% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. ZTS: 54.50 )
Ranked among companies with meaningful PE(NRI) only.
ZTS' s 10-Year PE(NRI) Range
Min: 27.31  Med: 36.01 Max: 59.81
Current: 54.5
27.31
59.81
P/B 18.65
ZTS's P/B is ranked lower than
97% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. ZTS: 18.65 )
Ranked among companies with meaningful P/B only.
ZTS' s 10-Year P/B Range
Min: 12.65  Med: 17.59 Max: 24.37
Current: 18.65
12.65
24.37
P/S 4.61
ZTS's P/S is ranked lower than
65% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. ZTS: 4.61 )
Ranked among companies with meaningful P/S only.
ZTS' s 10-Year P/S Range
Min: 3.11  Med: 3.73 Max: 5.25
Current: 4.61
3.11
5.25
PFCF 45.38
ZTS's PFCF is ranked lower than
55% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. ZTS: 45.38 )
Ranked among companies with meaningful PFCF only.
ZTS' s 10-Year PFCF Range
Min: 25.57  Med: 45.36 Max: 90.29
Current: 45.38
25.57
90.29
POCF 33.05
ZTS's POCF is ranked lower than
59% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. ZTS: 33.05 )
Ranked among companies with meaningful POCF only.
ZTS' s 10-Year POCF Range
Min: 21.59  Med: 31.72 Max: 41.99
Current: 33.05
21.59
41.99
EV-to-EBIT 35.26
ZTS's EV-to-EBIT is ranked lower than
66% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. ZTS: 35.26 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9  Med: 26.30 Max: 29.6
Current: 35.26
20.9
29.6
Current Ratio 2.11
ZTS's Current Ratio is ranked lower than
55% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ZTS: 2.11 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s 10-Year Current Ratio Range
Min: 2.11  Med: 2.74 Max: 3.47
Current: 2.11
2.11
3.47
Quick Ratio 1.21
ZTS's Quick Ratio is ranked lower than
68% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ZTS: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s 10-Year Quick Ratio Range
Min: 1.21  Med: 1.48 Max: 2
Current: 1.21
1.21
2
Days Inventory 283.30
ZTS's Days Inventory is ranked lower than
94% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. ZTS: 283.30 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s 10-Year Days Inventory Range
Min: 117.43  Med: 277.80 Max: 288.46
Current: 283.3
117.43
288.46
Days Sales Outstanding 75.40
ZTS's Days Sales Outstanding is ranked lower than
54% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. ZTS: 75.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s 10-Year Days Sales Outstanding Range
Min: 74.75  Med: 75.43 Max: 91.07
Current: 75.4
74.75
91.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.72
ZTS's Dividend Yield is ranked lower than
74% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. ZTS: 0.72 )
Ranked among companies with meaningful Dividend Yield only.
ZTS' s 10-Year Dividend Yield Range
Min: 0.21  Med: 0.64 Max: 0.94
Current: 0.72
0.21
0.94
Dividend Payout 0.37
ZTS's Dividend Payout is ranked lower than
56% of the 394 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. ZTS: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
ZTS' s 10-Year Dividend Payout Range
Min: 0.22  Med: 0.25 Max: 0.31
Current: 0.37
0.22
0.31
Yield on cost (5-Year) 0.72
ZTS's Yield on cost (5-Year) is ranked lower than
77% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.64 vs. ZTS: 0.72 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21  Med: 0.64 Max: 0.94
Current: 0.72
0.21
0.94
Share Buyback Rate -0.10
ZTS's Share Buyback Rate is ranked higher than
74% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. ZTS: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
ZTS' s 10-Year Share Buyback Rate Range
Min: 0  Med: 0.00 Max: -0.1
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.23
ZTS's Price/Median PS Value is ranked lower than
52% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ZTS: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
ZTS' s 10-Year Price/Median PS Value Range
Min: 0.85  Med: 0.99 Max: 1.35
Current: 1.23
0.85
1.35
Earnings Yield (Greenblatt) (%) 2.79
ZTS's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ZTS: 2.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZTS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.74  Med: 3.80 Max: 4.8
Current: 2.79
2.74
4.8

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 4,751 4,815 5,040 5,298
EPS($) 1.65 1.92 2.25 2.55
EPS without NRI($) 1.65 1.92 2.25 2.55

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Bill Ackman is keeping on buying Zoetis Feb 24 2015 
Activist Investor Bill Ackman's Newest Additions to His Portfolio Feb 18 2015 
Feeling Good With This Med Company Jan 20 2015 
2015 - First Half Jan 01 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 

More From Other Websites
Zoetis, Inc. Earnings Q2, 2015 Sep 01 2015
Zoetis Completes Manufacturing Expansion in Lincoln Aug 20 2015
Zoetis to Participate in the 2015 Morgan Stanley Global Healthcare Conference Aug 18 2015
ZOETIS INC. Financials Aug 14 2015
Jim Cramer's Top Takeaways: Allergan, Disney, Clorox, Zoetis Aug 07 2015
Jim Cramer's 'Mad Money' Recap: This Stock Market Is No Bargain Aug 06 2015
ZOETIS INC. Files SEC form 10-Q, Quarterly Report Aug 06 2015
Zoetis Completes Acquisition of Poultry Hatchery Automation Technology Leader KL Products, Inc. Aug 06 2015
William Blair Ups Zoetis To Outperform, Says Guidance Is Conservative Aug 06 2015
The Quiet Shareholder Activist? Dan Loeb Seeks Baxter Board Seats Without Fiery Contest Aug 05 2015
Edited Transcript of ZTS earnings conference call or presentation 4-Aug-15 12:30pm GMT Aug 04 2015
Evercore ISI's Mark Schoenebaum Comments On Zoetis' Q2 Call Aug 04 2015
Zoetis Beats on Q2 Earnings and Revenues, Narrows View - Analyst Blog Aug 04 2015
Zoetis (ZTS) Beats on Q2 Earnings, Updates 2015 View - Tale of the Tape Aug 04 2015
Zoetis reports 2Q loss Aug 04 2015
Zoetis reports 2Q loss Aug 04 2015
Zoetis Reports Second Quarter 2015 Results Aug 04 2015
Q2 2015 Zoetis Inc Earnings Release - Before Market Open Aug 04 2015
ZOETIS INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 04 2015
Zoetis Reports Second Quarter 2015 Results Aug 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK